Soon after the Thai National Guidelines on HIV/AIDS Treatment and Prevention have recommended antiretroviral treatment regardless of CD4 counts and pre-exposure prophylaxis (PrEP) for those at high- risk, PREVENTION collaborated with USAID, CDC Thailand and the Ministry of Public Health to tryout a feasibility study of Test & Treat service with PrEP sub-study in community-based and facility-based settings. In community-based settings, PrEP service was integrated into Community-led Test & Treat study at RSAT Bangkok, SWING Bangkok and Pattaya, SISTERS. The two public health facilities include Lerdsin Hospital and Thammasat Hospital.
A total of 409 participants from four community-based organizations were enrolled in PrEP sub-study and 164 started PrEP (40%).
In Thailand, KPs still face severe stigma and discrimination which often leaves them inadequate at every stage of HV continuum of prevention, care and treatment. For this reason, Key Population-Led Health Services (KPLHS) model becomes indispensable for providing such services. PREVENTION saw the id
Two new rapid HIV tests by Alere™ have the potential to substantially decrease the window period for rapid tests. The Alere™ HIV Combo or a rapid fourth generation test, has recently been assessed at the Thai Red Cross Anonymous Clinic Laboratory in Bangkok, Thailand. Of 50 confirmed acute HIV sampl
This five-year study’s goal is to develop proper long-term management guidelines for people living with HIV (PLHIV) in Thailand targeted at preventable conditions such as metabolic disease and certain cancers. The information obtained from this study
This study will investigate preferences for HIV care among participants enrolled in the ‘Study to evaluate the feasibility of Community-based Test and Treat strategies among men who have sex with men and transgender women to increase the uptake of HI
Thailand aims to end its AIDS epidemic by 2030 by increasing HIV testing rates to 90% among members of key populations and providing all HIV-positive individuals with antiretroviral therapy, regardless of their CD4 count. Current estimates project th